Discover the Science of Health
The National Institutes of Health (NIH) has partnered with the Department of Defense (DoD) to build a central database on traumatic brain injuries. Funded at $10 million over four years, the Federal Interagency Traumatic Brain Injury Research (FITBIR) database is designed to accelerate comparative effectiveness research on brain injury treatment and diagnosis. It will serve as a central repository for new data, link to current databases and allow valid comparison of results across studies.
By isolating cells from patients’ spinal tissue within a few days after death, researchers funded by the National Institutes of Health have developed a new model of the paralyzing disease amyotrophic lateral sclerosis (ALS). They found that during the disease, cells called astrocytes become toxic to nerve cells — a result previously found in animal models but not in humans. The new model could be used to investigate many more questions about ALS, also known as Lou Gehrig’s disease.
Memories are fragile; initially forming and then retrieving them are both dependent on new protein synthesis in the brain, and both processes are vulnerable to disruption. A number of agents are known that can impair memory and these can certainly be useful — for example, in treating post-traumatic stress disorder (ptsd). Enhancing memory, however, has proven more difficult. Yet as noted in The New York Times last week [1], two different research groups have recently reported enhancing memory in rats [2-3]. Of note is the fact that they did so utilizing independent molecular pathways.
Recent research by Michielsen and colleagues has demonstrated that “mirror therapy”, which can be given at home, results in significant, albeit modest, improvement in arm, wrist and hand movement abilities of stroke patients [1]. Mirror therapy is where the arm with impaired movement is placed behind a mirror and the unimpaired arm is reflected in the mirror, giving the appearance to the patient that when the unimpaired arm is moved, the impaired arm is also moving.
The single largest cause of adult disability in the developed world is ischemic stroke, in which blood flow in or to the brain is blocked. It precipitates immense amounts of social and financial costs. Currently, therapies for stroke focus on prevention or acute phase treatments that arrest the stroke while it is happening. But many patients are not fortunate enough to get acute phase treatment and suffer neurological damage that leads to functional and cognitive impairment. Until now, there have been almost no options for such patients. But last February, a company called ReNeuron received approval to begin a clinical trial of neural stem cell therapy for disabled stroke patients [1]. Two patients have been treated thus far and the therapy appears to be safe.
